Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
AZN AstraZeneca	$78.20 +0.3%	$72.07	$61.24 ▼ $87.68	$242.48B	0.36	5.31 million shs	3.20 million shs
BMY Bristol Myers Squibb	$47.42 -0.9%	$47.23	$42.96 ▼ $63.33	$96.51B	0.36	13.36 million shs	3.60 million shs
GSK GSK	$38.95 -0.5%	$38.58	$31.72 ▼ $44.67	$79.42B	0.51	5.23 million shs	1.34 million shs
IMGN ImmunoGen	$31.23	$31.23	$3.61 ▼ $31.25	$8.32B	1.18	8.78 million shs	40 shs
IOVA Iovance Biotherapeutics	$2.52 +2.7%	$2.25	$1.64 ▼ $12.51	$910.05M	0.88	13.77 million shs	5.37 million shs
LLY Eli Lilly and Company	$675.49 +2.3%	$767.52	$623.78 ▼ $972.53	$639.33B	0.44	4.11 million shs	4.78 million shs
NVO Novo Nordisk A/S	$50.18 -1.4%	$65.84	$45.05 ▼ $139.74	$224.10B	0.63	11.39 million shs	7.35 million shs

The Best Nuclear Energy Stocks to Buy

Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
AZN AstraZeneca	+3.45%	+5.90%	+8.64%	+14.69%	-6.51%
BMY Bristol Myers Squibb	+2.86%	+6.68%	+0.97%	+4.59%	-2.59%
GSK GSK	+2.51%	+6.57%	+2.25%	+4.42%	-4.83%
IMGN ImmunoGen	0.00%	0.00%	0.00%	0.00%	0.00%
IOVA Iovance Biotherapeutics	+10.09%	-4.84%	+22.14%	+39.49%	-77.14%
LLY Eli Lilly and Company	+3.27%	-11.49%	-17.40%	-9.83%	-27.26%
NVO Novo Nordisk A/S	+2.23%	+12.33%	-26.14%	-22.96%	-61.88%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
AZN AstraZeneca	3.7033 of 5 stars	2.4	5.0	2.5	0.0	4.1	0.0	1.9
BMY Bristol Myers Squibb	4.7419 of 5 stars	2.1	5.0	4.2	4.0	2.9	2.5	1.3
GSK GSK	2.6325 of 5 stars	0.9	5.0	2.5	0.0	3.3	0.0	2.5
IMGN ImmunoGen	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
IOVA Iovance Biotherapeutics	4.5393 of 5 stars	3.2	4.0	0.0	4.2	2.2	4.2	0.6
LLY Eli Lilly and Company	4.9993 of 5 stars	4.3	5.0	3.3	4.0	3.2	3.3	3.1
NVO Novo Nordisk A/S	4.6955 of 5 stars	4.0	5.0	2.5	0.0	3.1	0.0	3.1

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
AZN AstraZeneca	2.80	Moderate Buy	$86.00	9.97% Upside
BMY Bristol Myers Squibb	2.24	Hold	$56.38	18.90% Upside
GSK GSK	1.88	Reduce	$37.38	-4.03% Downside
IMGN ImmunoGen	0.00	N/A	N/A	N/A
IOVA Iovance Biotherapeutics	2.38	Hold	$11.90	373.16% Upside
LLY Eli Lilly and Company	2.65	Moderate Buy	$964.88	42.84% Upside
NVO Novo Nordisk A/S	2.07	Hold	$83.75	66.91% Upside

Current Analyst Ratings Breakdown

Latest LLY, NVO, IMGN, GSK, BMY, AZN, and IOVA Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/13/2025	LLY Eli Lilly and Company	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	Set Price Target	Overweight ➝ Overweight	$825.00
8/13/2025	NVO Novo Nordisk A/S	BNP Paribas Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Underperform ➝ Neutral
8/13/2025	LLY Eli Lilly and Company	Guggenheim Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$942.00 ➝ $875.00
8/13/2025	NVO Novo Nordisk A/S	BNP Paribas Exane Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Underperform ➝ Neutral	$54.00
8/11/2025	LLY Eli Lilly and Company	Deutsche Bank Aktiengesellschaft Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$1,010.00 ➝ $900.00
8/8/2025	IOVA Iovance Biotherapeutics	Wells Fargo & Company Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Overweight ➝ Overweight	$18.00 ➝ $14.00
8/8/2025	IOVA Iovance Biotherapeutics	Chardan Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$25.00 ➝ $20.00
8/8/2025	LLY Eli Lilly and Company	UBS Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$1,050.00 ➝ $895.00
8/7/2025	LLY Eli Lilly and Company	Leerink Partnrs Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Strong-Buy ➝ Hold
8/7/2025	LLY Eli Lilly and Company	Leerink Partners Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform ➝ Market Perform	$715.00
8/5/2025	BMY Bristol Myers Squibb	Daiwa America Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Strong-Buy ➝ Hold

(Data available from 8/14/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
AZN AstraZeneca	$54.07B	4.49	$6.53 per share	11.97	$14.45 per share	5.41
BMY Bristol Myers Squibb	$47.70B	2.02	$5.99 per share	7.91	$8.59 per share	5.52
GSK GSK	$40.10B	1.98	$5.69 per share	6.85	$9.40 per share	4.14
IMGN ImmunoGen	$287.61M	28.91	N/A	N/A	$0.71 per share	43.99
IOVA Iovance Biotherapeutics	$164.07M	5.55	N/A	N/A	$1.93 per share	1.30
LLY Eli Lilly and Company	$45.04B	14.19	$15.04 per share	44.92	$19.39 per share	34.84
NVO Novo Nordisk A/S	$42.12B	5.32	$3.93 per share	12.76	$5.73 per share	8.76

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
AZN AstraZeneca	$7.04B	$2.66	29.39	15.64	1.39	14.68%	32.84%	12.87%	N/A
BMY Bristol Myers Squibb	-$8.95B	$2.48	19.12	7.79	2.38	10.58%	80.04%	14.69%	10/30/2025 (Estimated)
GSK GSK	$3.29B	$2.16	18.03	8.38	1.66	10.81%	49.22%	11.31%	10/29/2025 (Estimated)
IMGN ImmunoGen	-$222.93M	-$0.31	N/A	84.41	N/A	-25.56%	-22.11%	-13.53%	N/A
IOVA Iovance Biotherapeutics	-$372.18M	-$1.23	N/A	N/A	N/A	-161.44%	-52.87%	-41.31%	N/A
LLY Eli Lilly and Company	$10.59B	$15.30	44.15	21.71	0.90	25.91%	92.72%	16.89%	10/29/2025 (Estimated)
NVO Novo Nordisk A/S	$14.64B	$3.64	13.79	10.77	1.71	35.60%	78.64%	24.51%	N/A

Latest LLY, NVO, IMGN, GSK, BMY, AZN, and IOVA Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/7/2025	Q2 2025	IOVA Iovance Biotherapeutics	-$0.29	-$0.33	-$0.04	-$0.33	$67.14 million	$59.95 million
8/7/2025	Q2 2025	LLY Eli Lilly and Company	$5.59	$6.31	+$0.72	$6.29	$14.40 billion	$15.56 billion
8/6/2025	Q2 2025	NVO Novo Nordisk A/S	$0.93	$0.97	+$0.04	$0.91	$77.51 billion	$11.69 billion
7/31/2025	Q2 2025	BMY Bristol Myers Squibb	$1.07	$1.46	+$0.39	$0.64	$11.32 billion	$12.27 billion
7/30/2025	Q2 2025	GSK GSK	$1.12	$1.23	+$0.11	$0.94	$7.92 billion	$10.64 billion
7/29/2025	Q2 2025	AZN AstraZeneca	$1.09	$1.09	N/A	$0.79	$14.08 billion	$14.46 billion

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
AZN AstraZeneca	$1.01	1.29%	N/A	37.97%	N/A
BMY Bristol Myers Squibb	$2.48	5.23%	N/A	100.00%	17 Years
GSK GSK	$1.71	4.39%	N/A	79.17%	N/A
IMGN ImmunoGen	N/A	N/A	N/A	N/A	N/A
IOVA Iovance Biotherapeutics	N/A	N/A	N/A	N/A	N/A
LLY Eli Lilly and Company	$6.00	0.89%	N/A	39.22%	11 Years
NVO Novo Nordisk A/S	$1.64	3.27%	N/A	45.05%	N/A

Latest LLY, NVO, IMGN, GSK, BMY, AZN, and IOVA Dividends

Announcement	Company	Period	Amount	Yield	Ex-Dividend Date	Record Date	Payable Date
7/31/2025	GSK GSK	quarterly	$0.4206	4.3%	8/15/2025	8/15/2025	10/9/2025
6/23/2025	LLY Eli Lilly and Company	quarterly	$1.50	0.78%	8/15/2025	8/15/2025	9/10/2025
7/29/2025	AZN AstraZeneca	semi-annual	$0.5050	2%	8/8/2025	8/8/2025	9/8/2025
8/7/2025	NVO Novo Nordisk A/S	semi-annual	$0.4119	2.4%	8/18/2025	8/18/2025	8/26/2025
6/17/2025	BMY Bristol Myers Squibb	quarterly	$0.62	5.25%	7/3/2025	7/3/2025	8/1/2025

(Data available from 1/1/2013 forward)

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
AZN AstraZeneca	0.55	0.86	0.67
BMY Bristol Myers Squibb	2.54	1.21	1.11
GSK GSK	1.07	0.87	0.57
IMGN ImmunoGen	0.13	5.70	5.65
IOVA Iovance Biotherapeutics	N/A	3.27	2.89
LLY Eli Lilly and Company	1.86	1.28	1.00
NVO Novo Nordisk A/S	0.52	0.78	0.56

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
AZN AstraZeneca	20.35%
BMY Bristol Myers Squibb	76.41%
GSK GSK	15.74%
IMGN ImmunoGen	90.50%
IOVA Iovance Biotherapeutics	77.03%
LLY Eli Lilly and Company	82.53%
NVO Novo Nordisk A/S	11.54%

Insider Ownership

Company	Insider Ownership
AZN AstraZeneca	N/A
BMY Bristol Myers Squibb	0.09%
GSK GSK	10.00%
IMGN ImmunoGen	5.07%
IOVA Iovance Biotherapeutics	10.30%
LLY Eli Lilly and Company	0.13%
NVO Novo Nordisk A/S	0.07%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
AZN AstraZeneca	94,300	3.10 billion	N/A	Optionable
BMY Bristol Myers Squibb	34,100	2.04 billion	2.03 billion	Optionable
GSK GSK	68,629	2.04 billion	1.84 billion	Optionable
IMGN ImmunoGen	277	266.26 million	252.76 million	Optionable
IOVA Iovance Biotherapeutics	500	361.85 million	324.58 million	Optionable
LLY Eli Lilly and Company	47,000	946.46 million	945.23 million	Optionable
NVO Novo Nordisk A/S	77,349	4.47 billion	4.46 billion	Optionable

LLY, NVO, IMGN, GSK, BMY, AZN, and IOVA Headlines

Recent News About These Companies

DEADLINE ALERT for SOC, LMT, NVO, and LINE: The Law Offices of Frank R. Cruz Reminds Investors of Class Actions on Behalf of Shareholders

1 hour ago | globenewswire.com

It's Time To Be All-In On Novo Nordisk

3 hours ago | seekingalpha.com

NVO LAWSUIT ALERT: The Gross Law Firm Notifies Novo Nordisk A/S Investors of a Class Action ...

4 hours ago | gurufocus.com

Novo Nordisk (NVO) vs Eli Lilly (LLY): Who’s Winning the Weight-Loss Drug War?

5 hours ago | moneymorning.comM

NVO LAWSUIT ALERT: The Gross Law Firm Notifies Novo Nordisk A/S Investors of a Class Action Lawsuit and Upcoming Deadline

5 hours ago | prnewswire.com

Inspire Trust Co. N.A. Purchases 6,000 Shares of Novo Nordisk A/S (NYSE:NVO)

5 hours ago | marketbeat.com

DSM Capital Partners LLC Acquires 49,175 Shares of Novo Nordisk A/S (NYSE:NVO)

August 14 at 7:33 AM | marketbeat.com

Holderness Investments Co. Reduces Stock Holdings in Novo Nordisk A/S (NYSE:NVO)

August 14 at 6:58 AM | marketbeat.com

Novo Nordisk launches weight-loss drug Wegovy in South Africa

August 14 at 6:12 AM | reuters.com

Rathbones Group PLC Grows Stock Holdings in Novo Nordisk A/S (NYSE:NVO)

August 14 at 5:33 AM | marketbeat.com

Why Novo Nordisk Stock Topped the Market Today

August 13 at 6:07 PM | fool.com

September 30, 2025 Deadline: Contact The Gross Law Firm to Join Class Action Suit Against NVO

August 13 at 4:41 PM | globenewswire.com

ROSEN, A TRUSTED AND LEADING LAW FIRM, Encourages Novo Nordisk A/S Investors to Secure Counsel Before Important Deadline in Securities Class Action - NVO

August 13 at 4:31 PM | globenewswire.com

Novo Nordisk A/S (NYSE:NVO) Trading Up 2.6% - Here's Why

August 13 at 4:19 PM | marketbeat.com

A Cure For Novo Nordisk

August 13 at 2:14 PM | seekingalpha.com

Novo Nordisk: The Falling Knife That Keeps Giving

August 13 at 12:06 PM | seekingalpha.com

Novo Nordisk A/S (NVO) Investors Who Lost Money Have Opportunity to Lead Securities Fraud Lawsuit

August 13 at 12:00 PM | prnewswire.com

Novo Nordisk Rises 6% So Far in August: How to Play the Stock

August 13 at 11:51 AM | zacks.com

INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Novo Nordisk A/S of Class Action Lawsuit and Upcoming Deadlines – NVO

August 13 at 10:47 AM | globenewswire.com

Novo Nordisk A/S (NYSE:NVO) Upgraded at BNP Paribas Exane

August 13 at 8:21 AM | marketbeat.com

Novo Nordisk A/S (NYSE:NVO) Shares Sold by GQG Partners LLC

August 13 at 7:40 AM | marketbeat.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

LLY, NVO, IMGN, GSK, BMY, AZN, and IOVA Company Descriptions

AstraZeneca NASDAQ:AZN

$78.20 +0.26 (+0.34%)

As of 01:08 PM Eastern

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company's marketed products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Lokelma, Roxadustat, Andexxa, Crestor, Seloken, Onglyza, Bydureon, Fasenra, Breztri, Symbicort, Saphnelo, Tezspire, Pulmicort, Bevespi, and Daliresp for cardiovascular, renal, metabolism, and oncology. Its marketed products also comprise Vaxzevria, Beyfortus, Synagis, FluMist, Soliris, Ultomiris, Strensiq, Koselugo, and Kanuma for covid-19 and rare disease. The company serves primary care and specialty care physicians through distributors and local representative offices in the United Kingdom, rest of Europe, the Americas, Asia, Africa, and Australasia. It has a collaboration agreement with Neurimmune AG to develop and commercialize NI006; BenevolentAI for drug discovery for systemic lupus erythematosus; and Absci Corporation for AI-driven drug discovery against an oncology target. The company was formerly known as Zeneca Group PLC and changed its name to AstraZeneca PLC in April 1999. AstraZeneca PLC was incorporated in 1992 and is headquartered in Cambridge, the United Kingdom.

Bristol Myers Squibb NYSE:BMY

$47.42 -0.44 (-0.91%)

As of 01:08 PM Eastern

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia. It also provides Yervoy for the treatment of patients with unresectable or metastatic melanoma; Empliciti for the treatment of multiple myeloma; Abecma for the treatment of relapsed or refractory multiple myeloma; Reblozyl for the treatment of anemia; Opdualag for the treatment of unresectable or metastatic melanoma; and Zeposia to treat relapsing forms of multiple sclerosis. In addition, the company offers Breyanzi for the treatment of relapsed or refractory large B-cell lymphoma; Onureg for the treatment of AML; Inrebic for the treatment of myelofibrosis; Camzyos for the treatment of symptomatic obstructive HCM to enhance functional capacity and symptom; Sotyktu for the treatment of moderate-to-severe plaque psoriasis; Augtyro for the treatment of locally advanced or metastatic ROS1-positive NSCLC; Revlimid, an oral immunomodulatory drug for the treatment of multiple myeloma; and Abraxane to treat breast cancer, NSCLC and pancreatic cancer. It sells products to wholesalers, distributors, pharmacies, retailers, hospitals, clinics, and government agencies. The company was formerly known as Bristol-Myers Company. Bristol-Myers Squibb Company was founded in 1887 and is headquartered in Princeton, New Jersey.

GSK NYSE:GSK

$38.95 -0.18 (-0.47%)

As of 01:08 PM Eastern

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D. The company offers shingles, meningitis, respiratory syncytial virus, flu, polio, influenza, and pandemic vaccines. It also provides medicines for HIV, oncology, respiratory/immunology, and other specialty medicine products, as well as inhaled medicines for asthma and chronic obstructive pulmonary disease, and antibiotics for infections. It has a collaboration agreement with CureVac to develop mRNA-based influenza vaccines, and with Wave Life Sciences and Elsie Biotechnologies, Inc for oligonucleotide platform development. The company was formerly known as GlaxoSmithKline plc and changed its name to GSK plc in May 2022. GSK plc was founded in 1715 and is headquartered in Brentford, the United Kingdom.

ImmunoGen NASDAQ:IMGN

ImmunoGen, Inc., a commercial-stage biotechnology company, focuses on developing and commercializing the antibody-drug conjugates (ADCs) for cancer patients. The company's product candidates include mirvetuximab soravtansine, an ADC targeting folate-receptor alpha (FRa), for the treatment of platinum-resistant ovarian cancer; and a cell-surface protein expressed in various epithelial tumors, including ovarian, endometrial, and non-small-cell lung cancers, as well as Pivekimab sunirine, a CD123-targeting ADC that is in Phase II clinical trial for treating acute myeloid leukemia and blastic plasmacytoid dendritic cell neoplasm. Its preclinical programs include IMGC936, an ADC in co-development with MacroGenics, Inc.; and IMGN151, an anti-FRa product candidate. The company has collaborations with Roche; Amgen/Oxford BioTherapeutics; Bayer HealthCare AG; Eli Lilly and Company; Novartis Institutes for BioMedical Research, Inc.; CytomX Therapeutics, Inc.; Fusion Pharmaceuticals Inc.; Debiopharm International SA; and MacroGenics, Inc. ImmunoGen, Inc. was founded in 1980 and is headquartered in Waltham, Massachusetts. As of February 12, 2024, ImmunoGen, Inc. operates as a subsidiary of AbbVie Inc.

Iovance Biotherapeutics NASDAQ:IOVA

$2.52 +0.07 (+2.65%)

As of 01:08 PM Eastern

Iovance Biotherapeutics, Inc., a commercial-stage biotechnology company, develops and commercializes cell therapies using autologous tumor infiltrating lymphocyte for the treatment of metastatic melanoma and other solid tumor cancers in the United States. The company offers Amtagvi, a tumor-derived autologous T cell immunotherapy used to treat adult patients with unresectable or metastatic melanoma; and Proleukin, an interleukin-2 product for the treatment of patients with metastatic renal cell carcinoma. It also develops lifileucel in combination with pembrolizumab to treat frontline advanced melanoma patients; LN-145 for the treatment of non-small cell lung cancer (NSCLC) and solid tumor cancers; IOV-4001, which is in Phase 1/2 IOV-GM1-201 clinical trial, for the treatment of NSCLC; and lifileucel for gynecological cancers. The company has collaborations and licensing agreements with WuXi Advanced Therapies, Inc.; National Institutes of Health; the National Cancer Institute; H. Lee Moffitt Cancer Center; The University of Texas M.D. Anderson Cancer Center; Cellectis S.A.; Novartis Pharma AG; and Boehringer Ingelheim Biopharmaceuticals GmbH. The company was formerly known as Lion Biotechnologies, Inc. and changed its name to Iovance Biotherapeutics, Inc. in June 2017. Iovance Biotherapeutics, Inc. was incorporated in 2007 and is headquartered in San Carlos, California.

Eli Lilly and Company NYSE:LLY

$675.49 +15.00 (+2.27%)

As of 01:08 PM Eastern

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity. It also provides oncology products, including Alimta, Cyramza, Erbitux, Jaypirca, Retevmo, Tyvyt, and Verzenio. In addition, the company offers Olumiant for rheumatoid arthritis, atopic dermatitis, severe alopecia areata, and COVID-19; Taltz for plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and non-radiographic axial spondylarthritis; Omvoh for ulcerative colitis; Cymbalta for depressive disorder, diabetic peripheral neuropathic pain, generalized anxiety disorder, fibromyalgia, and chronic musculoskeletal pain; Ebglyss for severe atopic dermatitis; and Emgality for migraine prevention and episodic cluster headache. Further, it provides Cialis for erectile dysfunction and benign prostatic hyperplasia; and Forteo for osteoporosis. It has collaborations with Incyte Corporation; Boehringer Ingelheim Pharmaceuticals, Inc.; F. Hoffmann-La Roche Ltd and Genentech, Inc.; Biologics, Inc., AbCellera Biologics Inc.; and Chugai Pharmaceutical Co., Ltd. The company was founded in 1876 and is headquartered in Indianapolis, Indiana.

Novo Nordisk A/S NYSE:NVO

$50.18 -0.72 (-1.42%)

As of 01:08 PM Eastern

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease. The Diabetes and Obesity care segment provides products for diabetes, obesity, cardiovascular, and other emerging therapy areas. The Rare Disease segment offers products in the areas of rare blood disorders, rare endocrine disorders, and hormone replacement therapy. The company also provides insulin pens, growth hormone pens, and injection needles. In addition, it offers smart solutions for diabetes treatment, such as smart insulin pens and Dose Check, an insulin dose guidance application. The company has a collaboration agreement with Aspen Pharmaceuticals to produce insulin products; and with Korro Bio, Inc. for the discovery and development of new genetic medicines to treat cardiometabolic diseases. Novo Nordisk A/S was founded in 1923 and is headquartered in Bagsvaerd, Denmark.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare MarketRank™

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest LLY, NVO, IMGN, GSK, BMY, AZN, and IOVA Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest LLY, NVO, IMGN, GSK, BMY, AZN, and IOVA Earnings

Compare Dividends

Latest LLY, NVO, IMGN, GSK, BMY, AZN, and IOVA Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

LLY, NVO, IMGN, GSK, BMY, AZN, and IOVA Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

LLY, NVO, IMGN, GSK, BMY, AZN, and IOVA Company Descriptions

AstraZeneca NASDAQ:AZN

Bristol Myers Squibb NYSE:BMY

GSK NYSE:GSK

ImmunoGen NASDAQ:IMGN

Iovance Biotherapeutics NASDAQ:IOVA

Eli Lilly and Company NYSE:LLY

Novo Nordisk A/S NYSE:NVO

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools